Table 3.

Distribution of gene mutations in high and low risk of 111 MDS patients.

Genes	Frequency (N = 111)	Low risk (N = 43) IPSS Score ≤ 3.5	High risk (N = 68) IPSS Score > 3.5	p value
SF3B1*	28 (25.2%)	16 (37.2%)	12 (17.6%)	0.026
SRSF2	22 (19.8%)	6 (14%)	16 (23.5%)	0.328
U2AF1	16 (14.4%)	5 (11.6%)	11 (16.2%)	0.588
ASXL1	11 (9.9%)	2 (4.7%)	9 (13.2%)	0.198
RUNX1	11 (9.9%)	2 (4.7%)	9 (13.2%)	0.198
TET2	10 (9%)	5 (11.6%)	5 (7.4%)	0.506
TP53**	10 (9%)	0	10 (14.7%)	0.006
ATM	7 (6.3%)	2 (4.7%)	5 (7.4%)	0.706
NRAS	6 (5.4%)	2 (4.7%)	4 (5.9%)	1.0
JAK2/3	6 (5.4%)	4 (9.3%)	2 (2.9%)	0.206
DNMT3A	5 (4.5%)	1 (2.3%)	4 (5.9%)	0.647
KMT2D	5 (4.5%)	2 (4.7%)	2 (2.9%)	1.0
NOTCH1	5 (4.5%)	3 (7%)	2 (2.9%)	0.374
ZRSR2	5 (4.5%)	1 (2.3%)	4 (5.9%)	0.647
SETBP1	5 (4.5%)	0	5 (7.4%)	0.154
KRAS	4 (3.6%)	1 (2.3%)	3 (4.4%)	1.0
NPM1	4 (3.6%)	2 (4.7%)	2 (2.9%)	0.640
IDH1/2	3 (2.7%)	2 (4.7%)	1 (1.5%)	0.558
BCOR	3 (2.7%)	0	3 (4.4%)	0.282
Other genes	2–1 (1.8–0.9%)	–	–	–